Skip to main content
Canada’s most-awarded newsroom for a reason
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
Canada’s most-awarded newsroom for a reason
$1.99
per week
for 24 weeks
// //

Edesa Biotech Inc NASDAQ: EDSA-Q

Today's Change
Volume
Real-Time Last Update Last Sale Cboe BZX Real-Time

More stories below advertisement

Latest Press Releases

Edesa Biotech Receives Canadian Approval to Test COVID-19 Drug as Rescue Therapy
AccessWire - Thu Jan 13, 6:55AM CST
AccessWire - PRTGAM
Thu Jan 13, 6:55AM CST
- Phase 3 study will focus on critically ill patients, many of whom have run out of effective drug treatment options TORONTO, ON / ACCESSWIRE / January 13, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company...
Opening to ’22 Features Job Figures Friday
Baystreet.ca - Baystreet - Fri Dec 31, 2021
Baystreet - SYNDTGAM
Fri Dec 31, 2021
MondayU.S.Economic LookaheadMarkit manufacturing Purchasing Managers Index (Dec)Featured EarningsJefferies ...
Edesa Biotech Reports Fiscal Year 2021 Results
AccessWire - Tue Dec 28, 2021
AccessWire - PRTGAM
Tue Dec 28, 2021
TORONTO, ON / ACCESSWIRE / December 28, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the fiscal year ended September...
Edesa Biotech Marks Enrollment Milestone in Dermatitis Study
AccessWire - Wed Dec 1, 2021
AccessWire - PRTGAM
Wed Dec 1, 2021
TORONTO, ON / ACCESSWIRE / December 1, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has completed enrollment of more than 75% of...
Edesa Biotech Extends COVID-19 Clinical Study to Poland
AccessWire - Thu Nov 4, 2021
AccessWire - PRTGAM
Thu Nov 4, 2021
- Expansion to European Union country follows favorable Phase 2 results - Company focusing on critically ill hospitalized patients TORONTO, ON / ACCESSWIRE / November 4, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical...
Edesa Biotech Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized COVID-19 Patients
AccessWire - Mon Sep 20, 2021
AccessWire - PRTGAM
Mon Sep 20, 2021
- Study unblinded due to strong efficacy signal for 28-day mortality endpoint - Critically ill patients demonstrated a 68.5% reduction in the risk of dying when treated with EB05 over Standard of Care - Data monitoring board recommends...
Edesa Biotech to Present at the H.C. Wainwright Global Investment Conference
AccessWire - Thu Sep 9, 2021
AccessWire - PRTGAM
Thu Sep 9, 2021
TORONTO, ON / ACCESSWIRE / September 9, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr. Par Nijhawan, Chief Executive Officer, will...
Edesa Biotech Enrolls More Than 525 COVID-19 Patients Ahead of Schedule
AccessWire - Thu Aug 26, 2021
AccessWire - PRTGAM
Thu Aug 26, 2021
- Delta variant contributes to rapid enrollment amid growing scientific rationale for targeting Toll-like Receptor 4 (TLR4) Blinded interim analysis from Phase 2/3 study expected in current quarter TORONTO, ON / ACCESSWIRE / August 26, 2021 /...
Edesa Biotech Reports Fiscal 3rd Quarter 2021 Financial Results
AccessWire - Fri Aug 13, 2021
AccessWire - PRTGAM
Fri Aug 13, 2021
TORONTO, ON / ACCESSWIRE / August 13, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and nine months ended...
iOnctura Strengthens Management With Appointment of Sean A. MacDonald as Chief Business Officer
Globe NewsWire - Thu Aug 5, 2021
Globe NewsWire - PRTGAM
Thu Aug 5, 2021
GENEVA, Switzerland, Aug. 05, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, today announces the appointment of Sean A. MacDonald to...

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2022.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies